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A B S T R A C T 
Breast cancer is the main type of cancer that affects women in the world. Treatment with chemotherapeutic 
agents for this type of cancer depends to a large extent on the phenotypic characteristics that appear in the 
tumor, such as some receptors. 
The treatment of breast cancer is complex since not all patients respond adequately to it and this is partly 
due to mechanisms of resistance to treatment. The resistance either acquired or intrinsic to 
chemotherapeutics against breast cancer is related to multiple genes and proteins that are actively involved 
in the development of resistance mechanisms, which may be inhibiting the binding of the drug to the target 
receptor, inhibiting the gene expression of the receptors, activating signaling pathways, inducing the action 
of transporters that expel the drug from the cell, etc. 
As a result of this review, the mechanisms of chemotherapeutic resistance in breast cancer derived from 
genes and proteins related to say disease are described, including genes related to different types of breast 
cancer, as well as with different therapeutic strategies. 
These genes and their products of expression include a wide range of interactions and activations of 
signalling pathways that trigger a poor response to treatment, which translates into a worse prognosis, higher 
risk of prevalence and death, favouring breast cancer to be the main cause of cancer death in women. 
Objective: Conduct an updated review of genes and proteins, that have been associated with conferring 
resistance to the different chemotherapeutic agents used for the treatment of breast cancer, including the 
mechanism of resistance and the type of cancer in which it is generated. 
Method: The search for indexed articles in the PubMed (https://www.ncbi.nlm.nih.gov/pubmed/) and 
ScienceDirect (http://www.sciencedirect.com) databases was performed, using the words “Breast cancer 
resistance” as a search criterion, articles published in the period 2015-2017 were selected. 
© 2018 Jonnathan Guadalupe Santillán-Benítez. Hosting by Science Repository. All rights reserved.    
 
Introduction 
Breast cancer is the predominant type of cancer in women with 25% of 
new cases and 15% of deaths caused by oncological diseases in the world 
[1]. Breast cancer is an extremely diverse and complex disease, where 
there is a marked tumour heterogeneity among patients, with specific 
subtypes of breast cancer associated with different prognoses. 
Differentiating breast tumour types is a key component of the clinical 
management process to ensure that patients receive the most appropriate 
type of treatment [2]. 
 
The treatment of breast cancer includes different types of therapies that 
can be local or systemic. Local therapy includes surgery and 
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radiotherapy, while chemotherapy, hormonal therapy and targeted 
therapy are among the systemic therapies [3]. 
 
The choice of treatment for breast cancer depends on the pathological 
characteristics that occur in each patient, such as the stage of the tumour, 
the state of the hormone receptors presents in the tumour, as well as the 
rate of recurrence, for example, in patients’ low recurrence, score 
hormonal therapy is recommended, while chemotherapy is mandatory 
for patients with high recurrence score. For patients with an intermediate 
recurrence score, the systemic therapy chosen takes into account risk 
factors such as age, tumour size, degree of tumour differentiation, 
extension of lymph node invasion, etc. [3, 4]. 
 
Avoiding resistance to therapeutic drugs is a critical point for researchers 
and clinicians, since it is desired to achieve successful therapy in patients 
with cancer. Drug resistance can be classified as intrinsic resistance or 
acquired resistance. Intrinsic resistance refers to patients who develop 
pre-existing factors and mediators of resistance before receiving 
chemotherapy. Acquired resistance on the other hand focuses on patients 
who were initially sensitive to chemotherapy but developed resistance 
during treatment [5]. 
 
There are different mechanisms that can lead to resistance to 
chemotherapeutic drugs such as inactivation of the drug, alteration of the 
site of action of the drug, drug efflux, repair of DNA damage, inhibition 
of cell death and epithelial–mesenchymal transition (EMT) [5]. 
 
Within these mechanisms influence different genes and proteins, as 
shown in Table 1, which respond against the treatment and therefore 
there is ineffectiveness of it, what leads to patients not improving their 
condition, below, certain genes and proteins associated with resistance 
to treatment against breast cancer are referred to. Genes and proteins 
associated with the resistance of breast cancer treatment:
 




Abbreviation Chemotherapeutics affected by resistance 
Type of cancer where 





Luminal A and B  
(RE+, RP+) 




Luminal A and B  
(RE+, RP+) 
Initiation complex of the eIF4F 
translation 
eIF4F Tamoxifen 
Luminal A and B  
(RE+, RP+) 
Leptin LEP Tamoxifen 
Luminal A and B  
(RE+, RP+) 
Mucin-1 protein MUC-1 Bortezomib, trastuzumab, tamoxifen 
Luminal A and B  
(RE+, RP+), positive Her-2 
Glutathione S-transferase P1  GSTP-1 
Anthracyclines and taxanes such as: adriamycin, 
daunomycin, epirubicin, docetaxel, paclitaxel, 
cyclophosphamide and doxorubicin 
Breast carcinoma in general 
β-glucosidase  GBA Paclitaxel Breast carcinoma in general 
ESR-1 Gene ESR-1 
Aromatase inhibitors such as: letrozole, anastrozole, 
exemestane 
Luminal A and B  (RE+, 







Luminal A and B  
(RE+, RP+) 
Interleukin 33 IL-33 Tamoxifen 
Luminal A and B  
(RE+, RP+) 
Factor E2F8 E2F8 Cisplatin Breast carcinoma in general 
Gene/Protein resistance effectors Abbreviation Chemotherapeutics affected by resistance Type of cancer where 
resistance is presented 
Mucin 4  MUC4 Trastuzumab Positive Her-2 
ATP binding cassette transport 
protein G2 
ABCG2 Mitoxantrone and camptothecin, topotecan and 
irinotecan derivatives 
Metastatic breast cancer 
Survivin BIRC-5 Taxans, kinesin inhibitors and mTOR inhibitors Breast carcinoma in general 
Brachyury protein / SIRT1 gene T/SIRT1 Tamoxifen Luminal A and B  
(RE+, RP+) 
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Membrane cell adhesion 
molecule 
MCAM  CD146 Tamoxifen Luminal A and B  
(RE+, RP+) 
Cyclin E CCNE-1 Aromatase inhibitors such as: letrozole, anastrozole, 
exemestane 
Luminal A and B  (RE+, 
RP+)in postmenopausal 
women. 
Nuclear factor enhancer of the 
kappa light chains of activated B 
cells 
NF-κB RTK inhibitors such as trastuzumab, bevacizumab or 
imatinib 
Breast cancer triple negative 
marker 
Krüppel-like factor 4 KLF4 Tamoxifen Luminal A and B  
(RE+, RP+) 
Cancerous protein phosphatase 
2A inhibitor 
CIP2A Tamoxifen Luminal A and B  
(RE+, RP+) 
p95-HER2 p95-HER2 Trastuzumab 
T-DM1 
Positive Her-2 
Exostosin 1 EXT1 Doxorubicin Breast carcinoma in general 
Cytochrome P450 2D6 CYP2D6 Tamoxifen Luminal A and B  
(RE+, RP+) 
 
Phosphoserine aminotransferase 1 (PSAT1) 
 
PSTA1 is an amino-transferase enzyme involved in the conversion of 
phospho-pyruvate, which is derived from the oxidation of 3-
phosphoglycerate, to phosphoserine [6]. Phosphoserine is then converted 
to serine by the enzyme phosphoserine phosphatase and is further 
converted to glycine to feed the nucleotide biosynthesis pathway. Along 
with this, it has been shown that the serine biosynthetic pathway is a 
critical factor in tumorigenesis and resistance to breast cancer therapy 
[6]. 
 
PSAT1 has been positively associated with the expression of some 
signaling pathways such as JAK / STAT and the activation of some 
receptors for cytokines such as IL4R and IL21R [6]. The IL4R receptor 
has been associated with the metabolic reprogramming of tumour cells 
in favour of an increase in glucose uptake and glutamine metabolism, 
whereas the expression of IL21R has been linked to the proliferation of 
breast cancer cells in the MDA-MB 231 cell line, in addition the binding 
of IL21 to its receptor promotes the activation of several signalling 
cascades, such as the JAK-STAT pathway, with differential effects 
related to tissue expression [6]. 
 
The JAK-STAT signalling pathway induces metabolic interruptions in 
tumour cells and facilitates the progression of the cell cycle by 
promoting the activation of cyclin-dependent kinases, so that the 
enrichment of PSAT1 is able to increase the expression of the pathway 
and because the JAK-STAT pathways and cytokines are directly related 
to inflammation, they contribute to the growth and spread of the tumour 
[6]. Therefore, an increase in the presence of PSAT1 protein and mRNA 
levels is significantly associated with the poor outcome of treatment with 
tamoxifen in breast cancer [6]. 
 
Embryonic transcription factor SOX9 
 
The estrogen receptor (ER) drives the growth of most luminal breast 
cancers, which is the main goal of endocrine therapy. Although ER 
blockade with drugs such as tamoxifen is very effective, one of the main 
clinical limitations is the development of endocrine resistance, this can 
be seen in Figure 1, which shows the action of estrogen and tamoxifen 
on the estrogen receptor and some molecules involved in resistance to 
this therapy [7]. 
 
It has been identified that treatment with tamoxifen promotes a complex 
called RUNX2-ER, which facilitates the positive regulation of the 
embryonic transcription factor SOX9, which is a transcription factor that 
regulates stem and progenitor cells in adult tissues. Recently it has been 
shown that they have a key role in the development of metastases in 
triple negative and HER2-positive breast cancer. It has been found that 
SOX9 is also expressed in breast cancers positive to estrogen receptor 
alpha, where it increases with progression, and plays an important role 















Figure 1: Action of estrogen and tamoxifen on the estrogen receptor. 
Molecules that inhibit the effect of tamoxifen, generating resistance 
 
It was shown that SOX9 is regulated in tamoxifen resistant cells 
(TAMR) by the ER α-RUNX2 complex, the proliferation of TAMR cells 
is dependent on SOX9, and this regulation is sufficient to cause 
resistance to estrogen deprivation and decreased sensitivity to treatment 
with tamoxifen [7]. 
 
Initiation complex of the eIF4F translation 
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The translation initiation complex eIF4F consists of an RNA helicase 
(eIF4A), a scaffold protein (eIF4G) and the eukaryotic translation 
initiation factor of the 4E cap binding protein (eIF4E), which is the 
limiting component of the complex. Evidence from multiple experiments 
suggests that malignancies driven by different oncogenic pathways 
converge and depend on the hyperactivation of the eIF4F translation 
machinery. It has been identified that in breast cancer cells resistant to 
tamoxifen there is a hyperactivation of the eIF4F pathway, which 
prevents the correct function of this therapeutic agent in the control of 




Leptin, the product of the Ob gene, is a cytokine released by adipose 
tissue. It acts as a multifunctional peptide hormone that can modulate 
broad biological processes, including appetite regulation, reproductive 
function, immune response, angiogenesis, etc. Leptin exerts its function 
by binding to its receptor (ObR), where the long ObRb isoform contains 
the full-length intracellular domain and has a total signalling potential 
[9]. 
 
Leptin plays an important role in the progression of breast cancer and 
interferes with the action of tamoxifen, since it interferes with the action 
of this treatment in breast cancer cells through the activation of 
signalling pathways ERK1 / 2 and STAT3 [9]. 
 
Recent studies have shown that the signal transduction pathway ERK1 / 
2 is important in the signalling of leptin to promote the growth, 
proliferation and migration of MCF-7 cells [9]. 
Overexpression of leptin-mediated cyclin D1 may also be associated 
with leptin-induced tamoxifen resistance in breast cancer, since leptin 
was found to induce a robust increase in cyclin D1 expression mediated 
by activation of STAT3 [9]. 
 
The overexpression of cyclin D1 is an alteration that participates in the 
interruption of the cell cycle in human tumours and serves as a critical 
interface between hormonal signalling and tumorigenesis, so 
overexpression of cyclin D1 correlates with poor prognosis in ER-
positive breast cancer and affects the response of tamoxifen in breast 
cancer cell lines [9]. 
 
Mucin1 protein (MUC1) 
 
The MUC1 protein is a glycosylated transmembrane protein of the 
epithelium, whose main function is to protect cells from the stresses 
induced by the external environment [10]. During the stress condition, 
MUC1 generates the transduction of survival signals into the interior of 
the cell, essential to maintain its functionality [10]. 
 
Recent studies have shown that a domain of this protein known as 
cytoplasmic domain MUC1 (MUC1-C) accelerates the development of 
resistance to several cancer therapeutics including bortezomib, 
trastuzumab and tamoxifen [10]. MUC1-C promotes the development of 
resistant mechanisms through signalling in the cell membrane and 
activation of signal transduction pathways [11]. 
 
The overexpression of MUC1-C in breast cancer cells triggers resistance 
to tamoxifen, by means of the following mechanism, where the 
phosphorylation of the cytoplasmic tail is able to interact with the ERα 
nuclear estrogen receptor. In the case of resistance to anticancer 
therapeutic agents, ER leads to sustained downstream signalling. Even 
in the presence of therapeutic agents, the aberrant activation of the PI3K 
/ AKT pathway in the progression of the breast tumour leads to the 
inhibition of GSK3 and the activation of Bcl-2, thus blocking the 
apoptotic process [11]. 
 
Glutathione S-transferase P1 (GSTP1) 
 
Glutathione S-transferase P1 (GSTP1), an enzyme that belongs to the 
family of metabolic phase II enzymes, is fundamental in the 
detoxification of potentially harmful chemical compounds by 
conjugating these compounds with glutathione [12]. Studies have 
identified that an overexpression of the enzyme GSTP1 participates as 
an agent that promotes resistance to chemotherapy in patients with breast 
cancer, especially in the treatments with adriamycin, daunomycin, 
epirubicin, docetaxel, paclitaxel, cyclophosphamide and doxorubicin 
[12]. 
 
There are different mechanisms that explain the resistance caused by this 
enzyme, one of them corresponds to an increase in the excretion of drugs 
because they are conjugated with glutathione, which gives them greater 
polarity and water solubility [12]. Another mechanism involves the 
presence of exosomes containing high levels of GSTP1 that appear to be 
essential for conferring resistance to anticancer drugs and are proposed 





β-glucosidase is a lysosomal enzyme that cleaves the glucosidic bond of 
glucosylceramide to generate ceramide and release glucose. It has been 
found to be involved in some pathologies such as Gaucher's disease and 
Parkinson's disease because defects in their activity lead to the 
accumulation of lipid substrates [13]. 
 
This enzyme has been linked to breast cancer, since an increase in the 
activity of β-glucosidase has been observed in breast cancer cells. By 
analysing different breast cancer cell lines, it was concluded that the high 
activity of β-glucosidase is a common phenomenon in breast cancer 
regardless of the different cell origins and genetic background [13]. 
 
It has been found that the activation of β-glucosidase results in the 
promotion of growth in the cells of the breast and the stimulation of the 
oncogenic pathway by increasing the levels of phosphorylation of the 
essential molecules involved in the PI3K / Akt / mTOR pathway [13]. 
Treatment with chemotherapy does not affect the activity of β-
glucosidase, suggesting that this enzyme is not involved in the response 
of breast cancer cells to chemotherapy. However, the inhibition of β-
glucosidase significantly increased the efficacy of paclitaxel. These data 
clearly demonstrate that the inhibition of β-glucosidase is capable of 
sensitizing breast cancer cells to chemotherapy and is an important factor 
in avoiding resistance to therapy in breast cancer [13]. 
 
Genes and proteins associated with chemotherapeutic resistance in breast cancer             5 
 
Clinical Oncology & Research   doi:10.31487/j.COR.2018.02.006     Volume 1(2): 5-10 
ESR-1 gene 
 
Recent studies have shown changes in subclonal structure through 
treatment interventions using cytotoxic and endocrine therapy. Recently, 
several genomic mechanisms of resistance to various therapies have 
been discovered, with the mutations in ESR1, the gene that codes for the 
estrogen receptor, being the most described and studied in the context of 
endocrine resistance [14]. Mutations are grouped in the ligand-binding 
domain of ESR1 and activate the estrogen receptor in the absence of the 
estrogen ligand. These mutations have been detected almost exclusively 
in the context of acquired endocrine therapy, typically with aromatase 
inhibitors, and more frequently where sensitivity to endocrine therapy 
was previously observed, suggesting that these mutations are associated 





Endocrine therapies include selective modulators of estrogen receptors 
such as tamoxifen and aromatase inhibitors such as anastrozole and 
letrozole. In the case of the alpha estrogen receptor, mutations have been 
identified that result in ligand-independent receptor activation and 
changes in microRNA expression [15].  
 
The miRNAs are small non-coding RNAs with an average size of 22 
nucleotides that post-transcriptionally regulate gene expression by 
binding to the 30 untranslated region (30UTR) of miRNAs to suppress 
translation or promote mRNA degradation [15]. These miRNAs have 
specific expression profiles for cancer, since they have been implicated 
in the regulation of breast cancer characteristics, including cell 
proliferation, cell death, apoptosis, the immune response, the energy cell 
cycle, the metabolism, replicative immortality, senescence, invasion and 
metastasis [15, 16]. 
 
An example of this is miRNA-222, which reduces the expression of 
FOXO1 which is one of the members of the O subfamily (FOXO) and 
which acts as a tumor suppressor, regulating many biological processes 
that involve the apoptotic response, the regulation of the cell cycle, cell 
differentiation and cellular metabolism [17]. 
 
Some examples of miRNAs, which are actively involved in resistance to 
endocrine treatment of breast cancer are. miRNA-221/222, miRNA-342-
3 p, miRNA-873 who negatively regulate the expression of the estrogen 
receptor alpha, which provides fewer sites of action for endocrine 
therapies and, therefore, in combination with other deregulated miRNAs, 
serves as a mechanism for resistance [15]. 
 
Another mechanism that associates resistance to treatment in breast 
cancer with miRNAs is that involving miRNA-342-3p, where the loss of 
said miRNA was associated with a concomitant loss in the expression of 
estrogen receptor alpha and resulted in resistance to tamoxifen therapy.  
It has also been determined that forced overexpression of miR-342-3p 
sensitized MCF7 breast cancer cells to apoptosis induced by tamoxifen 
[16]. 
 
Interleukin 33 (IL-33) 
 
IL-33, belongs to the family of cytokines 1 (IL-1), is a double-function 
protein that acts as an alarming extracellular cytokine and as an 
intracellular nuclear factor. IL-33 is constitutively expressed in epithelial 
barrier tissues and lymphoid organs, maintaining the barrier function 
under normal conditions, and is released as a warning signal of cell 
damage or stress. In patients with breast cancer, serum IL-33 is 
significantly higher and correlates with levels of VEGF, MMP-11 and 
PDGF-C that indicate a poor prognosis [18]. The expression of IL-33 in 
tumor tissues participates in the prediction of aggressive phenotype of 
cancer cells and increased involvement of lymph node involvement in 
patients with breast cancer, Likewise, signaling of the IL-33 / ST2 
complex promotes the progression of breast cancer through the support 
of inflammation and tumorigenesis, facilitating the expression of pro-
angiogenic VEGF and attenuating tumor necrosis [18]. 
 
An additional mechanism states that IL-33 contributes to tumor immune 
evasion by promoting the expansion and immunosuppressive function of 
myeloid suppressor cells. These findings consider IL-33 as a pro-cancer 
cytokine important in the development of breast cancer [18]. The 
expression of IL-33 in tumor cells predicts a higher activity of ALDH, a 
greater expression of SOX2, a decrease in the expression of the estrogen 




The E2F8 factor acts as a transcription activator that positively regulates 
the expression of CCNE1 and CCNE2 through interacting directly with 
their respective gene promoter, thereby promoting the proliferation of 
cancer cells [19]. Cisplatin is one of the most successful and commonly 
used chemotherapeutic drugs; however, tumors initially sensitive to 
chemotherapeutic agents usually develop resistance to these drugs, 
which is the main cause of relapse, metastasis and, finally, death related 
to cancer [19]. 
 
The treatment with cisplatin leads directly to the activation of the control 
point in the G2 / M phase, which subsequently leads to cellular apoptosis 
to eliminate the damaged cells. This activation of the control point occurs 
predominantly in the late phases S and G2, while the cells in phase M 
are reported to be hypersensitive to cisplatin. It has been shown that 
overexpression of E2F8 factor prevents cisplatin-induced cellular 
apoptosis in MCF-7 cells by shortening the arrest of G2 / M cell phases 
[19]. 
 
Brachyury protein / SIRT1 gene 
 
The brachyury protein is a necessary transcription factor for the 
specification of the mesoderm during the development of the embryo, 
but it is absent in adults recently, this protein has been associated with 
the tumor aggressiveness in several types of tumors such as breast cancer 
[20]. 
 
The brachyury protein is found to be expressed in samples of breast 
cancer tumors and cell lines; which is associated with an increased risk 
of recurrence; and affects tumorigenesis of breast cancer, including 
proliferation, migration, tumor dissemination and increased resistance to 
chemotherapy [20]. SIRT 1 is an oncogene that is found to be expressed 
in malignant tumors of the prostate, breast, pancreas and liver. It plays a 
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critical role in multiple aspects of resistance to cancer chemotherapy and 
promotes the survival of cancer cells [20]. 
 
It has been found that overexpression of the brachyury protein reduces 
the expression of SIRT1. Silencing of SIRT1 results in resistance to 
tamoxifen. This suggests that over expression of the brachyury protein 





MCAM, also called CD146 or MUC18, was identified for the first time 
in malignant melanoma and was shown to be a key oncogene driving the 
progression of melanoma and metastasis. The new clinical evidence 
indicates that the presence of MCAM confers a poor prognosis in 
patients with breast cancer [21]. It has been shown that MCAM is over 
expressed in cancer of basal type or with over expression of Her-2, but 
not in luminal cancers, likewise an inverse correlation has been found 
between the expression of MCAM and the expression of ERa in cell lines 
of breast cancer [21]. 
 
Since the effects of tamoxifen are mediated primarily by its binding to 
ER, loss of ER expression may confer resistance to treatment. It is 
suggested that the mechanism by which MCAM suppresses the 
expression of ERa is given transcription level by the regulation of Slug 
expression, since it is suggested that Slug binds directly to box E in the 





Cyclin E, a key regulatory protein that controls the transition between 
the G1 phase and the S phase in cells, is post translationally modified by 
proteolytic cleavage to generate cyclin E low molecular weight isoforms 
(LMW-E). These isoforms of cyclin E have been identified in different 
types of cancer such as: breast cancer, ovarian cancer, melanoma, 
colorectal cancer, lung cancer and renal cell carcinoma and are 
associated with a decrease in patient survival [22]. 
 
It has been identified that LMW-E are able to generate resistance to 
aromatase inhibitors (anastrozole, letrozole, and exemestane) that 
interfere with the enzymatic conversion of androgens to estrogens, but 
not with the biosynthesis of ovarian estrogens, making them effective 
only in postmenopausal patients [22]. The mechanism by which the 
expression of LMW-E mediates the resistance to aromatase inhibitor 
therapy is an alteration of the cell cycle of these cells in the transition 
from G1 to S. Specifically, the expression of LMW-E induces a greater 
number of arrested cells in the S phase, and due to the LMW-E mediated 
phosphorylation of pRb, cells can no longer be stopped in the G1 phase 
of the cell cycle [22]. 
 
Most endocrine therapies mediate their cytostatic effects causing the 
arrest of cells in the G1 phase of the cell cycle, thus inhibiting cell 
proliferation. Changes in the G1-S-S transition can be considered as an 





Triple-negative breast cancer (TNBC) is defined as a specific subtype of 
epithelial breast tumors, negative for expressing the estrogen receptor 
(ER), the progesterone receptor (PR) and the HER2. Contrary to other 
types of tumors, a special chemotherapy protocol has not been 
established to treat TNBC [23]. 
 
The absence of the ER / PR / HER2 overexpression pattern has made 
endocrine therapy with tamoxifen, aromatase inhibitors and therapies 
directed by HER2 useless for this type of cancer. In addition, TNBC is 
resistant to anthracyclines and taxanes, making the number of powerful 
therapeutic agents more restricted [23]. 
 
Recent studies have shown that tyrosine kinase (RTK) receptors are 
overexpressed in TNBC. Multiple members of these cell surface 
receptors have been identified and have been shown to play a key role in 
the regulation of essential cellular processes, including proliferation, 
differentiation, cell survival, migration and cell cycle control [23]. 
 
The epidermal growth factor receptor (EGFR), the fibroblast growth 
factor receptor (FGFR), the platelet-derived growth factor receptor 
(PDGFR), the vascular endothelial growth factor receptor (VEGFR) and 
the receptor insulin-like growth factor (IGF1-R) are the most important 
RTK presented in TNBC cells. However, chemotherapy with its 
selective inhibitors, which include trastuzumab, bevacizumab or 
imatinib, does not show significant improvement or decrease in the rate 
of progression of this type of cells [23]. 
 
Nuclear factor B (NF-κB) is involved in the expression of pro-
inflammatory proteins including cytokines, chemokines and adhesion 
molecules. Tumors can increase the activity of NF-κB by increasing the 
release of stromal cell cytokines and fibroblasts in the tumor 
microenvironment. Overexpression of NF-κB has been found in the 
TNBC and since it is the point of convergence of several signaling 
pathways transduced by RTK, it is suggested that overexpression of NF-
κB can be considered as one of the main reasons why RTK inhibitors do 
not induce the desired responses in clinical trials [23]. 
 
The activation of NF-κB leads to the expression of several pro-
inflammatory cytokines that generate a favorable microenvironment for 
tumor propagation in conjunction with growth factors, which lead to the 
formation of new mutations in cancer cells and the further development 
of resistance to agents of chemotherapy with RTK inhibitors. Within 
these pro-inflammatory cytokines, interleukin 6 and interleukin 8 are 
included, who develop crosstalk’s with RTKs and NF-κB. This 
mechanism may be the response to resistance to chemotherapy despite 
the administration of RTK inhibitors [23]. 
 
An additional mechanism is based on the fact that some external 
stimulators such as reactive oxygen species (ROS) and hypoxia-induced 
factor (HIF) can promote the activation of NF-κB. These stimulators 
have been cataloged as factors inducing chemo-resistance, which leads 
to the conclusion that the overexpression of NF-κB participates in the 
development of resistance to RTK inhibitors [23]. 
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Survivin 
 
Survivin is a protein that acts as an inhibitor of apoptosis, by inhibiting 
caspases 3 and 7. It also inhibits cell death by interfering with the 
processing of caspase-9, the main inhibitor in the intrinsic pathway of 
apoptosis. It has been determined that the expression of this protein is 
minimal in normal tissues and is expressed in a large number of 
malignant tumors, where their levels of expression correlate positively 
with a more aggressive condition and a poor clinical outcome, which has 
made it a target for diagnosis, prognosis and for cancer therapies [24]. 
The overexpression of survivin in cancer can overcome the control 
points of the cell cycle to facilitate the aberrant progression of 
transformed cells through mitosis, in addition it has been demonstrated 
that the expression of survivin induces transcriptional changes in the 
tissue microenvironment promoting tumorigenesis [24]. 
 
The positive regulation of survivin contributes to establish resistance to 
taxanes, kinesin inhibitors and mTOR inhibitors in breast cancer cells, 
this has been demonstrated by performing survivin inhibition assays in 
samples resistant to chemotherapy and inducing the anticancer activity 
of these drugs, and it was found that by suppressing the activity of 
survivin, chemotherapy provides good results [25]. 
 
These data reinforce the hypothesis that survivin is a mediator of 
resistance to chemotherapy and it is suggested that the increase of this 
protein in cancer tissues is an unfavorable prognostic marker, which is 
associated with an increased risk of recurrence [25]. 
 
Mucin 4 (MUC4) 
 
The mucin family (MUC) consists of glycosylated transmembrane 
proteins. Overexpression of some members of this family such as 
MUC1, MUC4 and MUC16, has been found in several human 
carcinomas, including breast cancer [26]. The MUC4 protein has three 
domains (NIDO, AMOP and VWD) that have not been found in any 
other protein belonging to the mucin family and functions as a ligand for 
the tyrosine kinase of the ErbB2 receptor [26]. 
 
Overexpression of MUC4 favors tumor development and cancer 
progression. Said overexpression has been identified in 30% to 95% of 
all types of breast cancer, and it is related to lymph node metastases and 
vascular tumor emboli [27]. 
 
It has been found that the MUC4 protein participates actively in 
resistance to treatment with trastuzumab, which in addition to being used 
in standard chemotherapy has been shown to improve the outcome of 
treatment of the early stage of breast cancer, as well as in cancer of 
HER2-positive metastatic breast. However, despite this success, 
responses to trastuzumab have been hampered by several resistance 
mechanisms, including overexpression of MUC4 [27]. The mechanism 
by which MUC4 participates in resistance to trastuzumab, is that this 
large glycoprotein can considerably hinder the accessibility and, 
therefore, the binding of trastuzumab to the ectodomain HER2 through 
the formation of a ligand / modulator complex, which impairs effective 
treatment with trastuzumab [27]. 
 
Polymorphism of the factor (V) of Leiden (F5 rs6025) 
 
Patients with cancer often suffer from a systemic activation of blood 
coagulation that can be attributed to the cancer itself or to its treatment. 
This excess of coagulation is reflected in increased risk of venous 
thrombosis, and it is widely accepted that the hemostatic system 
participates in neovascularization, tumor growth and metastatic spread, 
especially through the signaling of the tissue factor pathway. (TF) [28]. 
Activated protein C (APC) is an enzyme that is generated from protein 
C of the zymogen by the action of thrombin bound to thrombomodulin, 
which participates in the negative regulation of coagulation. The 
reduction of sensitivity to the anticoagulant function of APC, commonly 
referred to as resistance to APC, is an established risk factor for 
thrombosis in the general population [28]. 
 
APC resistance is mainly caused by Leiden factor (V) polymorphism (F5 
rs6025), which leads to poor inactivation of FVa, as well as impaired 
APC-cofactor activity of FV in the inactivation of FVIIIa [28]. The 
presence of acquired resistance APC has been shown in several types of 
cancer, including breast cancer, which may increase the risk of venous 




ATP-binding cassette transport proteins (ABCs) comprise a large 
superfamily of membrane proteins that are present in all living organisms 
from bacteria, fungi, plants and animals [29]. It has been identified that 
overexpression of ABC multispecific transporters plays an important 
role in the resistance of tumors to chemotherapeutic drugs, which leads 
to insufficient concentrations of the drug within the cancer cell, resulting 
in a failure of the therapy [ 29]. 
 
The mechanism by which this process is carried out is due to the fact that 
the ABC transporters use the energy of ATP hydrolysis to expel their 
substrates from the cell, commonly against a concentration gradient, 
promoting a conformational change and facilitating the active efflux of 
a variety of anticancer substrates [30]. Because structurally unrelated 
drugs are affected by this type of resistance, it is called multidrug 
resistance (MDR) [29,30]. 
 
ABCG2 also known as breast cancer resistance protein is a transporter 
medium consisting of 655 amino acids and possessing only one cytosolic 
nucleotide binding domain (NBD) and one transmembrane domain 
(TMD) [29]. 
 
ABCG2 recognizes and transports numerous anticancer drugs, including 
conventional chemotherapeutic molecules and small targeted therapeutic 
molecules such as the cytostatic mitoxantrone and camptothecin 
derivatives topotecan and irinotecan [29]. It is also able to expel some 
photosensitizers such as feoforbide A and protoporphyrin IX suggesting 
that ABCG2 is a possible cause of cellular resistance to photodynamic 
therapy in cancer [29]. 
 
Kruppel-like factor 4 (KLF4) 
 
The Kruppel-like factor 4 is a transcription factor that participates in the 
regulation of various cellular processes such as cell growth, proliferation 
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and differentiation, as well as the self-renewal of stem cells and the 
maintenance of pluripotency [31]. 
 
KLF4 possesses a transactivation domain and a repression domain, 
which together determine the specificity of the transcriptional regulatory 
activity of KLF4 through interaction with other factors and modulation 
of DNA binding efficiency [31, 32]. The activity of KLF4 is negatively 
regulated by the phosphorylation of ERK1 and ERK2 in serine 132, 
which results in the induction of differentiation of embryonic stem cells 
[32]. It has been shown that the expression of KLF4 is a poor prognostic 
factor for early breast and skin cancer, which corroborates its oncogenic 
role, it has also been shown that some of Krüppel's factors, such as KLF4 
and KLF15, can suppress the progression of ERα-dependent cancer [33]. 
 
The level of expression of KLF4 and ERα are positively correlated and 
patients who are sensitive to treatment with tamoxifen show a higher 
expression of KLF4, as well as a better disease-free survival after 
treatment. In vitro experiments have shown that KLF4 levels in 
tamoxifen-resistant cell lines are low, and that a higher expression of 
KLF4 leads to an increased sensitivity to tamoxifen [33]. It is proposed 
that KLF4 contributes to the sensitivity of tamoxifen in breast cancer 
through the modification of the phosphorylation of ERK and p38 
signalling and highlights the importance of the interaction of the KLF4 / 
MAPK signal to regulate the tamoxifen resistance of the breast cancer 
[33]. 
 
Cancerous inhibitor of the protein phosphatase 2A (CIP2A)  
 
CIP2A is an inhibitor of cellular protein phosphatase 2A (PP2A), which 
contributes to the immortalization and malignant transformation of 
human cells [34]. It has been determined that the levels of this protein 
are over-expressed in human breast cancer tissues, so its presence allows 
the diagnosis and prognosis of breast cancer, therefore it is useful as a 
diagnostic marker for this disease, in addition to being detectable in 
blood, which gives it greater value, as it is easily detectable [3, 4]. It has 
been found that tamoxifen-induced apoptosis in breast cancer is 
associated with the down-regulation of CIP2A and p-AKT, likewise the 
membranous expression of CIP2A is significantly higher in patients with 
tamoxifen resistance, however the mechanism by which resistance is 
generated is not yet fully glimpsed [35]. 
 
Membranous CIP2A is an indicator of resistance to tamoxifen in breast 
cancer with positive hormone receptors. It is considered that it may be 
useful to select patients with positive estrogen receptor at risk of 




T-DM1 is an antibody-drug complex used as a new tool for the treatment 
of breast cancer HER2 positive. It is a complex compound obtained by 
the conjugation of trastuzumab and the potent cytotoxic drug derived 
from Mayanism DM1, which is able to inhibit cell division and induce 
cell death [36]. 
 
The binding of T-DM1 to HER2-positive cells by said receptor allows 
the internalization of this complex by endocytosis and proceeds to its 
subsequent intraliposomal proteolytic degradation. However, its clinical 
activity is limited by inherent or acquired pharmacological resistance. 
[36]. The overexpression of p95HER2 is one of the molecular 
mechanisms of resistance to trastuzumab, since it has been shown that 
the expression levels of p95HER2 are sensitive but not specific in the 
determination of trastuzumab resistance. 
 
The mechanism by which p95-HER2 exerts its action to provide 
resistance to T-DM1, is that this isoform of the HER2 receptor lacks a 
specific binding site to trastuzumab, so that the drug cannot exert its 
biological action [38]. 
 
Exostosin 1 (EXT1) 
 
Exostoxin 1 is a type II transmembrane glycoprotein that is regulated by 
the endoplasmic reticulum (ER) and is involved in the biosynthesis of 
heparan sulphate (HS) on the cell surface [39]. It has been identified that 
in MCF7 / ADR cells (doxorubicin-resistant breast cancer cell line) the 
EXT1 glycoprotein is highly expressed, which is reflected in an increase 
in EMT expression (epithelial mesenchymal transition), an 
overexpression of P-gp (P-glycoprotein) and with-it greater resistance to 
chemotherapy [39]. 
 
This was checked by suppressing EXT1 mediated by siRNA in MCF7 / 
ADR cells, which eliminated heparan sulphate from the cell surface. In 
addition, it was observed that the epithelial mesenchymal tumour was 
repressed and the sensitization of these cells to the action of doxorubicin 
was increased [39]. These findings can be used as a new vision to define 
EXT1 as a new therapeutic target to counteract the chemoresistance of 
breast cancer in breast cancer patients with therapeutic resistance based 
on anthracyclines [39]. 
 
Cytochrome P450 2D6 (CYP2D6) 
 
CYP2D6 is an enzyme that is part of cytochrome P450 that participates 
in the metabolism of tamoxifen, converting it to 4-hydroxy-
Ndesmethyltamoxyphene (endoxifen), 4-hydroxy tamoxifen and N-
demethyltamoxifen [40]. The relative antiestrogenic potencies of 4-
hydroxy tamoxifen and endoxifen are comparable, but plasma 
concentrations of endoxifen are up to 10-fold higher in patients with 
functional CYP2D6. A problem that has been found is that there are 
people with different levels of functionality of this cytochrome, since it 
can present slow, intermediate and extensive metabolizers, which can 
compromise the levels of tamoxifen and its metabolites at the site of 
action and therefore generate a resistance to treatment [40]. 
 
Current and future focus of research on genes and proteins 
associated with chemotherapeutic resistance in breast cancer 
 
At present, the analysis of genes and their expression are the specialty of 
pharmacogenomics, which has the potential to revolutionize patient care 
by opening the door to personalized medicine in the field of 
pharmacotherapy and increase the likelihood of providing the right 
patient with the correct dose of the correct medication, using the correct 
route at the right time, improving its effectiveness and minimizing 
resistance to treatment [41]. 
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An important part to achieve this is the study of somatic and germline 
mutations, since these have a great impact on the prognosis of the disease 
and the response to therapy. Somatic mutations appear after an 
oncogenic process within the tumour tissue, whereas germline mutations 
are hereditary alterations found in the individual. These mutations can 
be used as risk biomarkers to optimize therapeutic decisions among the 
subpopulations of patients with breast cancer. Therefore, genetic 
information can be used both for the selection of effective therapy and 
to avoid treatments with an unacceptable risk of adverse reactions or 
resistance to chemotherapeutics [42]. 
 
Pharmacogenetics and pharmacogenomics determine the genetic 
differences to predict the safety, toxicity and efficacy of drugs between 
individuals and populations. Pharmacogenetics studies the variability in 
the response of the drug due to inheritance focusing on the genes 
involved in the metabolism of the drug, seeks to determine the genetic 
cause of unexpected drug responses by focusing on the genetic variation 
of pharmacokinetics (absorption, distribution, metabolism and excretion 
of the drug) as well as pharmacodynamics (receptors, channels and 
transporters of drug response) that are mechanisms that can participate 
in the development of resistance to treatment, while pharmacogenomics 
increases the understanding of the response to the drug by studying all 
the genes in the genome [42]. 
 
The analysis of the proteins involved in the resistance to chemotherapy 
is carried out through the use of proteomics, which is a complement for 
the investigation of the translation and modification of the genome and 
an effective tool for the comprehensive understanding of the expression 
of the genome [43]. 
 
However, pharmacogenomics and pharmacogenetics have not been 
sufficient to determine all the implications of genes and their expression 
in the development of resistance to treatment, which is why the post-
genomic era has begun, which deals with the application of omics 
technologies to biomedical and pharmaceutical research. Compared to 
traditional research methods, the application of omics sciences allows 
the exploration of the genome, transcriptome and proteome more 
broadly with greater sensitivity which can provide solutions for the 
discovery and validation of therapeutic targets, toxicity, pharmacology, 
molecular diagnosis, prognosis, and personalized medical attention [43]. 
 
With the application of the omics sciences, new areas of interest for the 
study of drug action and resistance mechanisms have emerged. One of 
these areas is the pharmacometabolomic, which studies the changes in 
the metabolome of an individual patient caused by the administration of 
a drug. It also allows us to analyse the effects of the drug on certain 
metabolic pathways involved in the mechanisms of variation in response 
to treatment, including resistance mechanisms [43]. 
 
One more field of application that is in development is the interact omics, 
which is a discipline that deals with studying both the interactions and 
the consequences of these interactions between proteins and other 
molecules within a cell (proteins, nucleic acids, lipids, carbohydrates, 
drugs). Among the most important interactions to be studied are the 
protein-protein interactions, the protein-DNA interactions and the 
protein-DNA-drug interactions, which would help us to identify new 
mechanisms of resistance to chemotherapeutics [43]. 
Conclusions 
 
Analysing the role of genes and proteins that compromise the effective 
response to a treatment against breast cancer is of vital importance, since 
this process of resistance generates that the patient does not respond to 
the treatment and his condition becomes more serious, leading to death. 
 
The discovery of new genes and proteins associated with resistance to 
chemotherapeutics, as well as their mechanism of resistance, can become 
risk biomarkers and possible therapeutic targets to guarantee the 
effectiveness of the treatment and with it a better prognosis and greater 
probability of cure.  
 
It is clear that the way to elucidate all the genes and proteins involved in 
resistance to the treatment of breast cancer is very long and complex, due 
to the multiple variants of treatments and types of breast cancer present, 
which exponentially increases the chances of finding new genes and 
proteins that participate in the intrinsic or acquired resistance to 
treatment against breast cancer. 
 
It is important to identify that resistance to the different therapeutic 
agents used to treat breast cancer regardless of the type of it, not only is 
it attributed to a particular gene or protein, but to a whole network of 
interactions between genes and proteins. These networks have been 
studied by the interact omics, however we still do not have complete 
knowledge of how these interactions are carried out and the scope they 
have, not only in the treatment of breast cancer, but from the analysis of 
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